Cambridge Investment Research Advisors, Inc. Madrigal Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 1,151 shares of MDGL stock, worth $392,226. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,151
Previous 1,429
19.45%
Holding current value
$392,226
Previous $303,000
17.16%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding MDGL
# of Institutions
336Shares Held
22.3MCall Options Held
960KPut Options Held
940K-
Janus Henderson Group PLC London, X02.21MShares$753 Million0.36% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$696 Million38.14% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$691 Million9.12% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$679 Million10.03% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$673 Million6.75% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.83B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...